
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
London -- A report published by Britain's National Prescribing Center saying that Fujisawa's Protopic (tacrolimus) and Novartis' Elidel (pimecrolimus) have only a limited role in the treatment of eczema was intended for general practitioners rather than dermatologists and refers mostly to mild cases treated in primary care settings.